Table 3.
T2–3 cases | T4 cases | |||||
---|---|---|---|---|---|---|
25(OH)D, nmol/L | < 50 | ≥50 | p a | < 50 | ≥50 | p a |
PFS | ||||||
No. at risk | 18 | 35 | 14 | 17 | ||
No. of events | 4 | 12 | 9 | 6 | ||
Univariable HR (95% CI) | 0.626 | Referent | 0.42 | 2.53 | Referent | 0.080 |
(0.202–1.94) | (0.895–7.12) | |||||
Multivariable HR (95% CI)b | 0.720 | Referent | 0.59 | 3.09 | Referent | 0.048 |
(0.220–2.38) | (1.01–9.45) | |||||
OS | ||||||
No. at risk | 18 | 35 | 14 | 17 | ||
No. of events | 2 | 5 | 7 | 1 | ||
Univariable HR (95% CI) | 0.714 | Referent | 0.69 | 10.8 | Referent | 0.026 |
(0.180–3.69) | (1.33–88.3) | |||||
Multivariable HR (95% CI)b | 0.783 | Referent | 0.79 | 17.6 | Referent | 0.010 |
(0.130–4.84) | (1.99–155) |
Abbreviations: 25(OH)D 25-hydroxyvitamin D, CI confidence interval, HR hazard ratio, OS overall survival, PFS progression-free survival, T tumor stage
aEstimated by Cox proportional hazards models
bAdjusted for age, sex, body mass index, and season (winter/spring and summer/fall as collapsed categories)